Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of “Buy” by Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMAGet Free Report) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last year is $21.00.

A number of brokerages have recently weighed in on OLMA. Capital One Financial restated an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Citigroup initiated coverage on Olema Pharmaceuticals in a research note on Tuesday, January 30th. They issued a “buy” rating and a $20.00 price objective for the company.

Read Our Latest Stock Analysis on OLMA

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $11.55 on Friday. The company has a fifty day moving average price of $13.20 and a 200-day moving average price of $13.15. The firm has a market cap of $645.88 million, a price-to-earnings ratio of -5.35 and a beta of 2.13. Olema Pharmaceuticals has a 1 year low of $3.00 and a 1 year high of $17.79.

Insider Activity

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 25,000 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $12.23, for a total transaction of $305,750.00. Following the completion of the transaction, the director now owns 876,283 shares in the company, valued at $10,716,941.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 23.50% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in Olema Pharmaceuticals by 20.6% during the 1st quarter. JPMorgan Chase & Co. now owns 28,800 shares of the company’s stock valued at $122,000 after buying an additional 4,928 shares in the last quarter. Acadian Asset Management LLC grew its stake in Olema Pharmaceuticals by 14.4% during the first quarter. Acadian Asset Management LLC now owns 115,076 shares of the company’s stock valued at $489,000 after acquiring an additional 14,454 shares in the last quarter. BlackRock Inc. increased its holdings in Olema Pharmaceuticals by 11.1% during the 1st quarter. BlackRock Inc. now owns 2,552,949 shares of the company’s stock worth $10,874,000 after acquiring an additional 254,785 shares during the period. Renaissance Technologies LLC purchased a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $1,054,000. Finally, Prelude Capital Management LLC bought a new position in Olema Pharmaceuticals in the 1st quarter valued at $61,000. 88.00% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Company Profile

(Get Free Report

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

Recommended Stories

Analyst Recommendations for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.